Redhill Biopharma LtdNASDAQ:RDHLNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4313
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4350/ 4
- Ask / Lots0.4501/ 1
- Open / Previous Close0.0000 / 0.4313
- Day Range---
- 52 Week Range
- Volume7,905
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RDHL |
|---|---|---|
| 09:32 ET | 19261 | 0.434 |
| 09:34 ET | 100 | 0.4378 |
| 09:43 ET | 200 | 0.4378 |
| 09:45 ET | 429 | 0.4378 |
| 09:52 ET | 1650 | 0.434 |
| 09:56 ET | 900 | 0.4378 |
| 09:59 ET | 1200 | 0.4378 |
| 10:06 ET | 600 | 0.43638 |
| 10:12 ET | 4608 | 0.434 |
| 10:26 ET | 100 | 0.434176 |
| 10:32 ET | 100 | 0.4357 |
| 10:46 ET | 137 | 0.4374 |
| 10:48 ET | 1489 | 0.4353 |
| 10:53 ET | 444 | 0.4347 |
| 10:55 ET | 302 | 0.4374 |
| 11:04 ET | 100 | 0.4349 |
| 11:22 ET | 2312 | 0.4332 |
| 11:33 ET | 8000 | 0.435 |
| 11:45 ET | 4340 | 0.4332 |
| 11:49 ET | 100 | 0.4331 |
| 11:56 ET | 100 | 0.433 |
| 12:00 ET | 100 | 0.43305 |
| 12:03 ET | 301 | 0.4331 |
| 12:09 ET | 100 | 0.4331 |
| 12:12 ET | 100 | 0.4331 |
| 12:16 ET | 6600 | 0.4331 |
| 12:36 ET | 175 | 0.433 |
| 12:38 ET | 1000 | 0.433 |
| 12:39 ET | 299 | 0.4331 |
| 12:48 ET | 596 | 0.433 |
| 12:50 ET | 4959 | 0.4369 |
| 12:52 ET | 1149 | 0.4369 |
| 12:57 ET | 220 | 0.436 |
| 01:08 ET | 5000 | 0.4316 |
| 01:17 ET | 100 | 0.4316 |
| 01:24 ET | 300 | 0.43167 |
| 01:26 ET | 100 | 0.4316 |
| 01:28 ET | 2000 | 0.43165 |
| 01:35 ET | 100 | 0.4317 |
| 01:37 ET | 15100 | 0.4312 |
| 01:39 ET | 444 | 0.43115 |
| 01:48 ET | 1000 | 0.43115 |
| 01:55 ET | 900 | 0.4311 |
| 01:57 ET | 1000 | 0.4369 |
| 02:06 ET | 1500 | 0.4367 |
| 02:08 ET | 1000 | 0.43385 |
| 02:09 ET | 5125 | 0.4367 |
| 02:27 ET | 489 | 0.436 |
| 03:00 ET | 500 | 0.435999 |
| 03:25 ET | 5383 | 0.4309 |
| 03:36 ET | 1100 | 0.431459 |
| 03:38 ET | 1349 | 0.43105 |
| 03:39 ET | 1827 | 0.4311 |
| 03:54 ET | 100 | 0.4359 |
| 03:57 ET | 400 | 0.432 |
| 03:59 ET | 100 | 0.4313 |
Apr 24, 2024
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study, from 7:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 8, 2024
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights, from 9:23AM ET on Monday Apr 08, 2024 by Dow Jones
9:23AM ET on Monday Apr 08, 2024 by Dow JonesPress Release: RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights, from 9:23AM ET on Monday Apr 08, 2024 by Dow Jones
9:23AM ET on Monday Apr 08, 2024 by Dow Jones
Apr 2, 2024
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price, from 7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Redhill Biopharma Ltd | 13.7M | 0.1x | --- |
Tonix Pharmaceuticals Holding Corp | 15.2M | 0.0x | --- |
Pulmatrix Inc | 6.9M | -0.5x | --- |
Petros Pharmaceuticals Inc | 4.6M | -0.1x | --- |
Kineta Inc | 6.4M | -0.4x | --- |
Stemcell Holdings Inc | 1.6M | 750.0x | --- |
Company Information
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Contact Information
- Headquarters
- 21 Ha'arba'a St.TEL AVIV-YAFO, Israel 6473921
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Dror Ben-Asher
- Chief Financial Officer
- Razi Ingber
- Chief Operating Officer
- Gilead Raday
- Senior Vice President - Regulatory Affairs
- Patricia Anderson
- Senior Vice President - Research and Development
- Reza Fathi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.7M |
|---|---|
Revenue (TTM) | $6.5M |
Shares Outstanding | 31.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.45 |
EPS | $3.69 |
Book Value | $0.11 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | 0.2x |
Operating Margin | 193.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
